Patrick Finn - Twist Bioscience Vice President of Sales and Marketing
| TWST Stock | USD 54.07 0.77 1.44% |
President
Mr. Patrick Finn, Ph.D. has served as our Vice President of Sales and Marketing since March 2015 and as our Senior Vice President of Commercial Operations since November 2018. Prior to joining us, Dr. Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications, sold predominantly to manufacturers in research and diagnostic markets from January 2012 to March 2015 since 2018.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 681 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 800 719 0671 |
| Web | https://www.twistbioscience.com |
Patrick Finn Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Finn against Twist Bioscience stock is an integral part of due diligence when investing in Twist Bioscience. Patrick Finn insider activity provides valuable insight into whether Twist Bioscience is net buyers or sellers over its current business cycle. Note, Twist Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Twist Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Finn over six months ago Disposition of 2207 shares by Patrick Finn of Twist Bioscience at 56.625 subject to Rule 16b-3 | ||
Patrick Finn over six months ago Disposition of 2207 shares by Patrick Finn of Twist Bioscience at 56.625 subject to Rule 16b-3 | ||
Patrick Finn over six months ago Disposition of 476 shares by Patrick Finn of Twist Bioscience at 48.002 subject to Rule 16b-3 | ||
Patrick Finn over six months ago Disposition of 2174 shares by Patrick Finn of Twist Bioscience at 30.121 subject to Rule 16b-3 |
Twist Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.1639) % which means that it has lost $0.1639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3836) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2025. Return On Capital Employed is likely to drop to -0.38 in 2025. Non Current Liabilities Total is likely to gain to about 86.5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Tang | Agilent Technologies | 50 | |
| Eric Sherbet | IQVIA Holdings | 60 | |
| Daniel Raskas | Danaher | 54 | |
| Rose Kidd | ICON PLC | N/A | |
| Reginald Seeto | Caredx Inc | 52 | |
| Simon Holmes | ICON PLC | 57 | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Rob Kotchie | IQVIA Holdings | N/A | |
| Robert Lutz | Danaher | 62 | |
| Jonah Kirkwood | Agilent Technologies | N/A | |
| Amol Chaubal | Waters | 49 | |
| Toby Juvenal | Castle Biosciences | 63 | |
| Rodney Gonsalves | Agilent Technologies | 59 | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| John Fesko | Natera Inc | 46 | |
| Cynthia Verst | IQVIA Holdings | N/A | |
| Diarmaid Cunningham | ICON PLC | 50 | |
| Joakim Weidemanis | Danaher | 55 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Sherry Buck | Waters | 55 | |
| Henrik AncherJensen | Agilent Technologies | 59 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 |
Twist Bioscience Corp Leadership Team
Elected by the shareholders, the Twist Bioscience's board of directors comprises two types of representatives: Twist Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Twist. The board's role is to monitor Twist Bioscience's management team and ensure that shareholders' interests are well served. Twist Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Twist Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emily Leproust, President CEO, Director | ||
| William Banyai, GM Development | ||
| Patrick Finn, Vice President of Sales and Marketing | ||
| Dennis JD, Chief VP | ||
| Kevin Yankton, VP Officer | ||
| Chet Gandhi, Chief Officer | ||
| Michael Fero, Chief Officer | ||
| Siyuan Chen, Chief Officer | ||
| Aaron Sato, Chief Officer | ||
| Dennis Cho, General VP | ||
| James Thorburn, Chief Officer | ||
| Erin Smith, Sr Policy | ||
| Adam Laponis, Chief Officer | ||
| Paula Green, Vice President of Human Resources | ||
| Angela Bitting, Chief Affairs | ||
| Robert Werner, VP Officer |
Twist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Twist Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.75) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 59.58 M | ||||
| Shares Owned By Insiders | 1.94 % | ||||
| Shares Owned By Institutions | 98.06 % | ||||
| Number Of Shares Shorted | 8.7 M | ||||
| Price To Book | 6.60 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.